Press Release
G2GBio has the best subject matter experts in the field of the injectable drug development.
|
G2GBio to accelerate its CDO·CDMO businesses with new patent for microsphere injectables containing 50%+ peptide drugs
2024.08.12
HIT 14351
|
|---|
The company has advanced a new platform for peptide drugs, demonstrating over 60% drug loading
![]()
G2GBio, specializing in long-acting injectables (LAI) for various small molecules and peptide drugs, announced on 12th that it has successfully produced a microsphere injectable containing 60% of the small molecule drug donepezil.
For over 30 years, PLGA microspheres have been used as LAI drug delivery systems for various small molecules and peptide drugs. However, to avoid injection site side effects, the administration of PLGA microspheres has been limited in both dosage and volume, restricting their commercialization to high-potency drugs.
These limitations are even more pronounced in self-administered subcutaneous injectables, where the microsphere volume must be kept under 100 mg and the injection volume below 1 mL. Although many companies have sought to increase the drug load within the microspheres to reduce the total administered amount, this remains a significant challenge.
G2GBio is leveraging its Innovative Long-Acting Microsphere Platform (InnoLAMP) technology to overcome these limitations.
Recently, G2GBio made a breakthrough by successfully manufacturing microsphere injectables containing 60% of the small molecule drug donepezil. Phase 1 clinical trials have confirmed a controlled release of donepezil for over a month, with no initial burst release. This is a significant improvement over the highest drug loading in a commercially available microsphere injectable to date - J&J's Risperdal Consta®, a schizophrenia drug containing 38.1% risperidone.
Furthermore, G2GBio has successfully developed a new microsphere injectable platform with peptide drugs such as semaglutide, cagrilintide, and tirzepatide for the treatment of diabetes and obesity, which guarantees over 50% drug loading while suppressing the initial burst. The production of high drug loading microspheres for peptide drugs is extremely complex due to their high water solubility and requires state-of-the-art technology. This achievement is all the more remarkable given that the highest drug loading currently available on the market is 27.6% for pasireotide pamoate - Novartis' Signifor® LAR, an acromegaly treatment.
After filing a related platform patent, G2GBio is set to accelerate its CDO and CDMO businesses. To date, G2GBio owns 116 patents, including 64 applications and 52 issued patents, both domestically and internationally.
G2GBio will showcase its newly developed technologies and relevant data at the PODD conference in Boston on October 28, 2024, to actively expand its global partnerships. |
